{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:07:35Z","timestamp":1778882855676,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ekir.2023.05.022","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T12:16:53Z","timestamp":1685362613000},"page":"1575-1584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome"],"prefix":"10.1016","volume":"8","author":[{"given":"Biswanath","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan Kumar Sinha","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Meis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.05.022_bib1","first-page":"CD002290","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","volume":"10","author":"Pravitsitthikul","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2023.05.022_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ekir.2023.05.022_bib3","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2015-0486","article-title":"Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome","volume":"136","author":"Basu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ekir.2023.05.022_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.05.022_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","article-title":"Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab","volume":"31","author":"Kamei","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroiddependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.05.022_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.05.022_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR inchildren with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ekir.2023.05.022_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","article-title":"Long-term outcome of childhood onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab","volume":"32","author":"Kamei","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib15","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid- dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"JASN"},{"key":"10.1016\/j.ekir.2023.05.022_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","article-title":"Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study","volume":"35","author":"Ravani","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2215\/CJN.00380116","article-title":"Ethnic differences in incidence and outcomes of childhood nephrotic syndrome","volume":"11","author":"Banh","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2023.05.022_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ekir.2023.05.022_bib20","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"CJASN"},{"key":"10.1016\/j.ekir.2023.05.022_bib21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B\u00a0cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2021050643","article-title":"Mycophenolate mofetil after rituximab for childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome","volume":"33","author":"Iijima","year":"2022","journal-title":"JASN"},{"key":"10.1016\/j.ekir.2023.05.022_bib23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently relapsing nephrotic syndrome have important effects on outcome","volume":"97","author":"Chan","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.05.022_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study","volume":"33","author":"Chan","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.05.022_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12882-020-02153-5","article-title":"Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome","volume":"21","author":"Basu","year":"2020","journal-title":"BMC Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923013177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923013177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:46:24Z","timestamp":1762832784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923013177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2468024923013177"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.05.022","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}